Efficacy and safety of anticoagulant treatment using new alternative antithrombotic agents in acute cardioembolic stroke with nonvalvular atrial fibrillation.

Efficacy and safety of anticoagulant treatment using new alternative antithrombotic agents in acute cardioembolic stroke with nonvalvular atrial fibrillation. - Efficacy and safety of anticoagulant treatment using new alternative antithrombotic agents in acute cardioembolic stroke with nonvalvular atrial fibrillation.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010477

Enrollment

Registered

2013-04-22

Start date

2013-04-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral infarction

Interventions

Patients within 48 hours after onset of cardioembolism with nonvalvular atrial fibrillation are treated with oral new alternative antithrombotic agents.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients within 48 hours after onset of cardioembolism with nonvalvular atrial fibrillation

Exclusion criteria

Exclusion criteria: 1)extensive cerebral infarction(more than one third of the middle cerebral artery territory) 2)severe dysphagia 3)hepatic function disorder (Child-Pugh B or C) 4)renal dysfunction (CCr<30ml/min) 5)anemia (Hb<10.0g/dl) 6)hemorrhagic event

Design outcomes

Primary

Measure	Time frame
early recurrent stroke within 14 days, all embolism within 14 days except ischemic stroke, all strokes within 14 days, all hemorrhagic event within 14 days	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026